<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03064113</url>
  </required_header>
  <id_info>
    <org_study_id>0059</org_study_id>
    <secondary_id>ACTRN12611000482965</secondary_id>
    <secondary_id>U1111-1120-8290</secondary_id>
    <nct_id>NCT03064113</nct_id>
  </id_info>
  <brief_title>Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thirty-two subjects diagnosed with COPD were enrolled, received each study treatment and
      completed the follow-up assessments. During each of the four study periods, subjects were
      admitted to the clinic on Day -1 and housed overnight until after the last spirometry
      measurement. Serial pulmonary function tests were performed and PK (pharmacokinetics) samples
      collected up to 25 hours. Subjects were discharged from the clinic on Day 2 after
      evaluations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were assigned to one of the 4-treatment sequence groups presented in the table above
      according to a randomization schedule supplied by the Sponsor before study initiation. The
      randomization scheme did not include assignments for replacement subjects.

      Subjects reported to their respective clinical research unit (CRU) on Admission/Day −1 for
      pre-randomization procedures and confirmation of eligibility (and continued eligibility for
      Periods 2 to 4). The unblinded pharmacist prepared and dispensed the nebulizers, according to
      the randomization schedule for each of the 4 periods. Dosing occurred in the morning,
      generally between 7 am and 9 am. For Periods 2 to 4, dosing occurred within ±30 minutes of
      the dosing time established in Period 1.

      Study drug was administered in the respective CRU under the supervision of study personnel.
      Single doses of TD-4208, ipratropium bromide, and placebo were administered in the clinical
      research unit (CRU) under the supervision of study personnel. Care was taken to avoid eye
      contact with study drugs. Residual drug solution remaining in the nebulizer (ie, in mL) was
      measured and recorded.

      The investigator or designee was responsible for maintaining accountability records for all
      study drug(s) in accordance with applicable government regulations and study procedures.

      The accountability record included entries for receipt, distribution or dispensing, and
      destruction of the material(s). Unused and expired study drugs were to be disposed of in
      accordance with written instructions from the Sponsor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline</measure>
    <time_frame>From predose to 25 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the FEV1 vs. Time Curve, Time-matched Difference From Placebo</measure>
    <time_frame>12 hr and 24 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the FEV1 vs. Peak FEV1, Time-matched Difference From Placebo</measure>
    <time_frame>12 hr and 24 hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25−75), as Related to FEV1</measure>
    <time_frame>12hr and 24hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25−75), as Related to FEV1</measure>
    <time_frame>12hr and 24hr</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>From predose to 25 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Forced Vital Capacity (FVC) vs. Time Curve</measure>
    <time_frame>0-24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease, COPD</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 = Placebo; Period 2 = TD-4208 700 μg; Period 3 = TD-4208 350 μg; Period 4 = Ipratropium 500 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 = TD-4208 700 μg; Period 2 = Ipratropium 500 μg; Period 3 = Placebo; Period 4 = TD-4208 350 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 = TD-4208 350 μg; Period 2 = Placebo; Period 3 = Ipratropium 500 μg; Period 4 = TD-4208 700 μg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1 = Ipratropium 500 μg; Period 2 = TD-4208 350 μg; Period 3 = TD-4208 700 μg; Period 4 = Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208 700 μg</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <other_name>Revefenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208 350 μg</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <other_name>Revefenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipratropium 500 μg</intervention_name>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of moderate stable Chronic Obstructive Pulmonary.

          -  Disease with FEV1/FVC &lt;0.7 at screening.

          -  Woman of non-childbearing potential.

          -  Female participants of childbearing potential must test negative for pregnancy and
             must be using a highly effective method of birth control during the study and for at
             least 1 month after completion of study dosing.

          -  Female participants must not be breastfeeding.

          -  Men must agree to use a highly effective method of birth control with partners of
             childbearing potential during the study and for 1 month after completion of study
             dosing.

          -  Current or past smoking history &gt;10 pack-years.

          -  Must be capable of performing reproducible spirometry maneuvers.

        Exclusion Criteria:

          -  History of significant respiratory disease other than COPD, and/ or requires daily
             long-term oxygen therapy.

          -  Exacerbation of COPD, lung infection within 6 weeks prior to study.

          -  Start of or change in dose of COPD treatment 4 weeks before study.

          -  Daily using of maintenance systemic/inhaled corticosteroids (&gt;1000 microgram of
             fluticasone propionate equivalent or &gt;5 mg prednisone).

          -  Use of bronchodilators or medication for the treatment of COPD, aspirin,
             anti-inflammatories for a specific time, prior to the first dose or is not willing to
             abstain from their use for the specified time periods prior to study dose
             administration.

          -  Symptomatic prostrate hypertrophy, bladder neck obstruction, active cancer, narrow
             angle glaucoma.

          -  Clinical significant hypersensitivity to medications.

          -  Participants have an uncontrolled hematologic, immunologic, renal, neurologic,
             hepatic, endocrine or other disease that may place participant at risk.

          -  Cerebrovascular, cardiovascular disease or abnormal ECG.

          -  History of drug or alcohol abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 20, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <results_first_submitted>June 12, 2017</results_first_submitted>
  <results_first_submitted_qc>October 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2019</results_first_posted>
  <last_update_submitted>November 15, 2019</last_update_submitted>
  <last_update_submitted_qc>November 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease, COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>21-May-2011 (FPFV) through 07-Oct-2011 (LPLV)</recruitment_details>
      <pre_assignment_details>Male and female subjects between the ages of 40 and 75 years-old with a clinical diagnosis of COPD and responsiveness to ipratropium bromide.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>Intervention 1 (Placebo) - [2 days], washout [7 days],
Intervention 2 (TD4208 700 μg) - [2 days], washout [7 days],
Intervention 3 (TD-4208 350 μg) - [2 days], washout [7 days],
Intervention 4 (Ipratropium 500 μg) - [2 days], washout [7 days]</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>Intervention 1 (TD-4208 700 μg) - [2 days], washout [7 days],
Intervention 2 (Ipratropium 500 μg) - [2 days], washout [7 days],
Intervention 3 (Placebo) - [2 days], washout [7 days],
Intervention 4 (TD-4208 350 μg) - [2 days], washout [7 days]</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>Intervention 1 (TD-4208 350 μg) - [2 days], washout [7 days],
Intervention 2 (Placebo) - [2 days], washout [7 days],
Intervention 3 (Ipratropium 500 μg) - [2 days], washout [7 days],
Intervention 4 (TD-4208 700 μg) - [2 days], washout [7 days]</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>Intervention 1(Ipratropium 500 μg) - [2 days], washout [7 days],
Intervention 2 (TD-4208 350 μg) - [2 days], washout [7 days],
Intervention 3 (TD-4208 700 μg) - [2 days], washout [7 days],
Intervention 4 (Placebo) - [2 days], washout [7 days]</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 2 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 3 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 4 (2 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence 1</title>
          <description>Intervention 1 (Placebo) - [2 days], washout [7 days],
Intervention 2 (TD-4208 700 μg) - [2 days], washout [7 days],
Intervention 3 (TD-4208 350 μg) - [2 days], washout [7 days],
Intervention 4 (Ipratropium 500 μg) - [2 days], washout [7 days]</description>
        </group>
        <group group_id="B2">
          <title>Sequence 2</title>
          <description>Intervention 1 (TD-4208 700 μg) - [2 days], washout [7 days],
Intervention 2 (Ipratropium 500 μg) - [2 days], washout [7 days],
Intervention 3 (Placebo) - [2 days], washout [7 days],
Intervention 4 (TD-4208 350 μg) - [2 days], washout [7 days]</description>
        </group>
        <group group_id="B3">
          <title>Sequence 3</title>
          <description>Intervention 1 (TD-4208 350 μg) - [2 days], washout [7 days],
Intervention 2 (Placebo) - [2 days], washout [7 days],
Intervention 3 (Ipratropium 500 μg) - [2 days], washout [7 days],
Intervention 4 (TD-4208 700 μg) - [2 days], washout [7 days]</description>
        </group>
        <group group_id="B4">
          <title>Sequence 4</title>
          <description>Intervention 1 (Ipratropium 500 μg) - [2 days], washout [7 days],
Intervention 2 (TD-4208 350 μg) - [2 days], washout [7 days],
Intervention 3 (TD-4208 700 μg) - [2 days], washout [7 days],
Intervention 4 (Placebo) - [2 days], washout [7 days]</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="8"/>
            <count group_id="B5" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.25" spread="7.48"/>
                    <measurement group_id="B2" value="63.25" spread="8.21"/>
                    <measurement group_id="B3" value="59.63" spread="3.67"/>
                    <measurement group_id="B4" value="64.88" spread="7.75"/>
                    <measurement group_id="B5" value="62.00" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline</title>
        <time_frame>From predose to 25 hours postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo administered via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>TD-4208 700 μg</title>
            <description>Single dose of TD-4208 700 μg administered via nebulizer</description>
          </group>
          <group group_id="O3">
            <title>TD-4208 350 μg</title>
            <description>Single dose of TD-4208 350 μg administered via nebulizer</description>
          </group>
          <group group_id="O4">
            <title>Ipratropium 500 μg</title>
            <description>Single dose of Ipratropium 500 μg administered via nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline</title>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1708.0" spread="32.7"/>
                    <measurement group_id="O2" value="1877.3" spread="32.7"/>
                    <measurement group_id="O3" value="1881.8" spread="32.7"/>
                    <measurement group_id="O4" value="1883.6" spread="32.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>173.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>112.4</ci_lower_limit>
            <ci_upper_limit>235.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>169.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>107.8</ci_lower_limit>
            <ci_upper_limit>230.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>175.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>114.1</ci_lower_limit>
            <ci_upper_limit>237.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the FEV1 vs. Time Curve, Time-matched Difference From Placebo</title>
        <time_frame>12 hr and 24 hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo administered via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>TD-4208 700 μg</title>
            <description>Single dose of TD-4208 700 μg administered via nebulizer</description>
          </group>
          <group group_id="O3">
            <title>TD-4208 350 μg</title>
            <description>Single dose of TD-4208 350 μg administered via nebulizer</description>
          </group>
          <group group_id="O4">
            <title>Ipratropium 500 μg</title>
            <description>Single dose of Ipratropium 500 μg administered via nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the FEV1 vs. Time Curve, Time-matched Difference From Placebo</title>
          <units>mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEV1 at 12hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1519.2" spread="30.9"/>
                    <measurement group_id="O2" value="1642.6" spread="31.4"/>
                    <measurement group_id="O3" value="1631.7" spread="30.9"/>
                    <measurement group_id="O4" value="1534.5" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1 at 24 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1533.8" spread="22.4"/>
                    <measurement group_id="O2" value="1670.4" spread="22.4"/>
                    <measurement group_id="O3" value="1636.6" spread="22.4"/>
                    <measurement group_id="O4" value="1509.6" spread="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean FEV1 at 12 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Slope</param_type>
            <param_value>112.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.5</ci_lower_limit>
            <ci_upper_limit>180.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean FEV1 at 12 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>123.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.6</ci_lower_limit>
            <ci_upper_limit>192.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean FEV1 at 12 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.659</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>15.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-53.5</ci_lower_limit>
            <ci_upper_limit>94.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean FEV1 at 24 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>102.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>54.1</ci_lower_limit>
            <ci_upper_limit>151.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean FEV1 at 24 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>136.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>87.8</ci_lower_limit>
            <ci_upper_limit>185.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Tx Difference of LS Mean FEV1 at 24 hr</non_inferiority_desc>
            <p_value>0.327</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>-24.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-72.9</ci_lower_limit>
            <ci_upper_limit>24.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the FEV1 vs. Peak FEV1, Time-matched Difference From Placebo</title>
        <time_frame>12 hr and 24 hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo administered via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>TD-4208 700 μg</title>
            <description>Single dose of TD-4208 700 μg administered via nebulizer</description>
          </group>
          <group group_id="O3">
            <title>TD-4208 350 μg</title>
            <description>Single dose of TD-4208 350 μg administered via nebulizer</description>
          </group>
          <group group_id="O4">
            <title>Ipratropium 500 μg</title>
            <description>Single dose of Ipratropium 500 μg administered via nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the FEV1 vs. Peak FEV1, Time-matched Difference From Placebo</title>
          <units>hr*mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262.1" spread="4.2"/>
                    <measurement group_id="O2" value="291.2" spread="4.2"/>
                    <measurement group_id="O3" value="288.5" spread="4.2"/>
                    <measurement group_id="O4" value="287.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-24 hrs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.2" spread="4.0"/>
                    <measurement group_id="O2" value="286.6" spread="4.0"/>
                    <measurement group_id="O3" value="281.3" spread="4.1"/>
                    <measurement group_id="O4" value="271.7" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean AUC, 0-12 hrs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>26.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.0</ci_lower_limit>
            <ci_upper_limit>34.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean AUC, 0-12 hrs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>29.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>20.8</ci_lower_limit>
            <ci_upper_limit>37.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean AUC, 0-12 hrs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>25.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.3</ci_lower_limit>
            <ci_upper_limit>33.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean AUC, 0-24 hrs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>20.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.1</ci_lower_limit>
            <ci_upper_limit>28.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean AUC, 0-24 hrs</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>25.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>17.4</ci_lower_limit>
            <ci_upper_limit>33.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean AUC, 0-24 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>10.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>18.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25−75), as Related to FEV1</title>
        <time_frame>12hr and 24hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo administered via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>TD-4208 700 μg</title>
            <description>Single dose of TD-4208 700 μg administered via nebulizer</description>
          </group>
          <group group_id="O3">
            <title>TD-4208 350 μg</title>
            <description>Single dose of TD-4208 350 μg administered via nebulizer</description>
          </group>
          <group group_id="O4">
            <title>Ipratropium 500 μg</title>
            <description>Single dose of Ipratropium 500 μg administered via nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow Rate (PEFR) From 25% to 75% of Vital Capacity (FEF25−75), as Related to FEV1</title>
          <units>L/sec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peak FEF 25-75% 24hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.0"/>
                    <measurement group_id="O2" value="0.9" spread="0.0"/>
                    <measurement group_id="O3" value="0.9" spread="0.0"/>
                    <measurement group_id="O4" value="0.9" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak FEF 25-75% 12hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.0"/>
                    <measurement group_id="O2" value="0.9" spread="0.0"/>
                    <measurement group_id="O3" value="0.9" spread="0.0"/>
                    <measurement group_id="O4" value="0.9" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 12 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 12 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 12 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 24 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 24 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.048</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 24 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25−75), as Related to FEV1</title>
        <time_frame>12hr and 24hr</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo administered via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>TD-4208 700 μg</title>
            <description>Single dose of TD-4208 700 μg administered via nebulizer</description>
          </group>
          <group group_id="O3">
            <title>TD-4208 350 μg</title>
            <description>Single dose of TD-4208 350 μg administered via nebulizer</description>
          </group>
          <group group_id="O4">
            <title>Ipratropium 500 μg</title>
            <description>Single dose of Ipratropium 500 μg administered via nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Flow From 25% to 75% of Vital Capacity (FEF25−75), as Related to FEV1</title>
          <units>L/sec</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>FEF 25-75% at 12 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.0"/>
                    <measurement group_id="O2" value="0.7" spread="0.0"/>
                    <measurement group_id="O3" value="0.7" spread="0.0"/>
                    <measurement group_id="O4" value="0.6" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEF 25-75% at 24 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.0"/>
                    <measurement group_id="O2" value="0.6" spread="0.0"/>
                    <measurement group_id="O3" value="0.6" spread="0.0"/>
                    <measurement group_id="O4" value="0.6" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 12 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 12 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.045</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0</ci_lower_limit>
            <ci_upper_limit>0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 12 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.503</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 24 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.183</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 24 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.422</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Tx Difference of LS Mean 24 hr</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.287</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.1</ci_lower_limit>
            <ci_upper_limit>0.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <time_frame>From predose to 25 hours postdose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo administered via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>TD-4208 700 μg</title>
            <description>Single dose of TD-4208 700 μg administered via nebulizer</description>
          </group>
          <group group_id="O3">
            <title>TD-4208 350 μg</title>
            <description>Single dose of TD-4208 350 μg administered via nebulizer</description>
          </group>
          <group group_id="O4">
            <title>Ipratropium 500 μg</title>
            <description>Single dose of Ipratropium 500 μg administered via nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2941.9" spread="771.4"/>
                    <measurement group_id="O2" value="2949.1" spread="623.5"/>
                    <measurement group_id="O3" value="2986.7" spread="800.8"/>
                    <measurement group_id="O4" value="2959.4" spread="696.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2873.4" spread="748.5"/>
                    <measurement group_id="O2" value="3166.9" spread="704.9"/>
                    <measurement group_id="O3" value="3119.3" spread="700.1"/>
                    <measurement group_id="O4" value="3339.7" spread="761.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2944.7" spread="718.8"/>
                    <measurement group_id="O2" value="3263.8" spread="676.2"/>
                    <measurement group_id="O3" value="3262.2" spread="810.1"/>
                    <measurement group_id="O4" value="3399.4" spread="789.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2927.2" spread="760.7"/>
                    <measurement group_id="O2" value="3324.7" spread="784.8"/>
                    <measurement group_id="O3" value="3328.8" spread="758.3"/>
                    <measurement group_id="O4" value="3394.1" spread="858.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2968.1" spread="747.3"/>
                    <measurement group_id="O2" value="3269.4" spread="801.2"/>
                    <measurement group_id="O3" value="3361.9" spread="787.3"/>
                    <measurement group_id="O4" value="3379.4" spread="829.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3062.5" spread="717.0"/>
                    <measurement group_id="O2" value="3363.1" spread="764.1"/>
                    <measurement group_id="O3" value="3408.8" spread="922.2"/>
                    <measurement group_id="O4" value="3441.6" spread="770.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3122.2" spread="774.5"/>
                    <measurement group_id="O2" value="3430.4" spread="858.6"/>
                    <measurement group_id="O3" value="3420.3" spread="912.0"/>
                    <measurement group_id="O4" value="3474.1" spread="815.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3177.8" spread="798.6"/>
                    <measurement group_id="O2" value="3386.3" spread="901.7"/>
                    <measurement group_id="O3" value="3340.9" spread="867.1"/>
                    <measurement group_id="O4" value="3368.8" spread="836.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3192.6" spread="794.3"/>
                    <measurement group_id="O2" value="3442.8" spread="849.5"/>
                    <measurement group_id="O3" value="3220.6" spread="960.7"/>
                    <measurement group_id="O4" value="3295.3" spread="889.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3197.2" spread="826.9"/>
                    <measurement group_id="O2" value="3259.4" spread="837.3"/>
                    <measurement group_id="O3" value="3301.6" spread="875.8"/>
                    <measurement group_id="O4" value="3305.2" spread="841.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2958.7" spread="686.0"/>
                    <measurement group_id="O2" value="3335.3" spread="848.5"/>
                    <measurement group_id="O3" value="3339.4" spread="749.7"/>
                    <measurement group_id="O4" value="3180.3" spread="815.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>11 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3156.2" spread="827.5"/>
                    <measurement group_id="O2" value="3296.2" spread="720.4"/>
                    <measurement group_id="O3" value="3295.5" spread="901.9"/>
                    <measurement group_id="O4" value="3162.3" spread="733.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3092.8" spread="714.8"/>
                    <measurement group_id="O2" value="3229.4" spread="859.7"/>
                    <measurement group_id="O3" value="3265.1" spread="842.1"/>
                    <measurement group_id="O4" value="3131.3" spread="737.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>14 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3114.4" spread="803.0"/>
                    <measurement group_id="O2" value="3333.1" spread="803.6"/>
                    <measurement group_id="O3" value="3319.1" spread="904.3"/>
                    <measurement group_id="O4" value="3123.8" spread="793.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>22 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3033.8" spread="669.4"/>
                    <measurement group_id="O2" value="3314.5" spread="802.1"/>
                    <measurement group_id="O3" value="3147.2" spread="754.4"/>
                    <measurement group_id="O4" value="3010.0" spread="596.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>23 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2999.7" spread="779.1"/>
                    <measurement group_id="O2" value="3349.4" spread="834.5"/>
                    <measurement group_id="O3" value="3232.2" spread="849.4"/>
                    <measurement group_id="O4" value="3006.3" spread="680.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3018.1" spread="758.2"/>
                    <measurement group_id="O2" value="3345.6" spread="810.6"/>
                    <measurement group_id="O3" value="3243.1" spread="864.9"/>
                    <measurement group_id="O4" value="3031.6" spread="703.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3172.8" spread="810.0"/>
                    <measurement group_id="O2" value="3392.5" spread="844.0"/>
                    <measurement group_id="O3" value="3295.2" spread="744.4"/>
                    <measurement group_id="O4" value="3219.4" spread="762.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Forced Vital Capacity (FVC) vs. Time Curve</title>
        <time_frame>0-24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single dose of placebo administered via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>TD-4208 700 μg</title>
            <description>Single dose of TD-4208 700 μg administered via nebulizer</description>
          </group>
          <group group_id="O3">
            <title>TD-4208 350 μg</title>
            <description>Single dose of TD-4208 350 μg administered via nebulizer</description>
          </group>
          <group group_id="O4">
            <title>Ipratropium 500 μg</title>
            <description>Single dose of Ipratropium 500 μg administered via nebulizer</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Forced Vital Capacity (FVC) vs. Time Curve</title>
          <units>hr*mL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74168.1" spread="1155.5"/>
                    <measurement group_id="O2" value="80057.0" spread="1155.3"/>
                    <measurement group_id="O3" value="78143.6" spread="1155.9"/>
                    <measurement group_id="O4" value="76822.7" spread="1155.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>3975.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2007.3</ci_lower_limit>
            <ci_upper_limit>5943.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>5888.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3924.4</ci_lower_limit>
            <ci_upper_limit>7853.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Difference of LS Mean</param_type>
            <param_value>2654.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>689.7</ci_lower_limit>
            <ci_upper_limit>4619.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 months (May-October 2011)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Single dose of placebo administered via nebulizer</description>
        </group>
        <group group_id="E2">
          <title>TD-4208 700 μg</title>
          <description>Single dose of TD-4208 700 μg administered via nebulizer</description>
        </group>
        <group group_id="E3">
          <title>TD-4208 350 μg</title>
          <description>Single dose of TD-4208 350 μg administered via nebulizer</description>
        </group>
        <group group_id="E4">
          <title>Ipratropium 500 μg</title>
          <description>Single dose of Ipratropium 500 μg administered via nebulizer</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Electrocardiogram T Wave peaked</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may communicate the trial results generated by the PI, but only after the first publication or presentation of the combined study results generated by all participating sites. The Sponsor can then review trial results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The Sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Development &amp; Medical Affairs</name_or_title>
      <organization>Theravance Biopharma</organization>
      <phone>1-855-633-8479</phone>
      <email>medinfo@theravance.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

